Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, phase I study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple doses of orally administered ASN120290 in Healthy young and elderly volunteers.

Trial Profile

A randomized, double-blind, placebo-controlled, phase I study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple doses of orally administered ASN120290 in Healthy young and elderly volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2018

At a glance

  • Drugs ASN 120290 (Primary)
  • Indications Progressive supranuclear palsy
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 18 Jul 2018 According to an Asceneuron media release, data from the study will be presented at the upcoming Alzheimer's Association International Conference (AAIC) (July 2018).
    • 18 Jul 2018 Status changed to completed, as reported in the Asceneuron media release.
    • 12 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top